105 related articles for article (PubMed ID: 21721161)
1. The value of postoperative/preadjuvant chemotherapy computed tomography in the management of patients with ovarian cancer.
Sala E; Mannelli L; Yamamoto K; Griffin M; Griffin N; Grant L; Parker R; Crawford R
Int J Gynecol Cancer; 2011 Feb; 21(2):296-301. PubMed ID: 21721161
[TBL] [Abstract][Full Text] [Related]
2. Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller.
Chi DS; Barlin JN; Ramirez PT; Levenback CF; Mironov S; Sarasohn DM; Iyer RB; Dao F; Hricak H; Barakat RR
Int J Gynecol Cancer; 2010 Apr; 20(3):353-7. PubMed ID: 20375796
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less.
Chi DS; Ramirez PT; Teitcher JB; Mironov S; Sarasohn DM; Iyer RB; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Brown CL; Aghajanian C; Gershenson DM; Hoskins WJ; Hricak H; Barakat RR
J Clin Oncol; 2007 Nov; 25(31):4946-51. PubMed ID: 17971592
[TBL] [Abstract][Full Text] [Related]
4. Early postoperative CT as a prognostic biomarker in patients with advanced ovarian, tubal, and primary peritoneal cancer deemed optimally debulked at primary cytoreductive surgery.
Lakhman Y; Akin O; Sohn MJ; Zheng J; Moskowitz CS; Iyer RB; Barakat RR; Sabbatini PJ; Chi DS; Hricak H
AJR Am J Roentgenol; 2012 Jun; 198(6):1453-9. PubMed ID: 22623562
[TBL] [Abstract][Full Text] [Related]
5. Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
Eskander RN; Kauderer J; Tewari KS; Mannel RS; Bristow RE; O'Malley DM; Rubin SC; Glaser GE; Hamilton CA; Fujiwara K; Huh WK; Ueland F; Stephan JM; Burger RA
Gynecol Oncol; 2018 Jun; 149(3):525-530. PubMed ID: 29550184
[TBL] [Abstract][Full Text] [Related]
6. Is postoperative computed tomography evaluation a prognostic indicator in patients with optimally debulked advanced ovarian cancer?
Lorusso D; Sarno I; Di Donato V; Palazzo A; Torrisi E; Pala L; Marchiano A; Raspagliesi F
Oncology; 2014; 87(5):293-9. PubMed ID: 25139548
[TBL] [Abstract][Full Text] [Related]
7. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
8. Surgical outcome prediction in patients with advanced ovarian cancer using computed tomography scans and intraoperative findings.
Kim HJ; Choi CH; Lee YY; Kim TJ; Lee JW; Bae DS; Kim BG
Taiwan J Obstet Gynecol; 2014 Sep; 53(3):343-7. PubMed ID: 25286788
[TBL] [Abstract][Full Text] [Related]
9. [Predictive value of preoperative abdominopelvic CT for optimal cytoreduction surgery in ovarian carcinoma].
Taïeb S; Bonodeau F; Leblanc é ; Vennin P; Fournier C; Besson P
Bull Cancer; 2000 Mar; 87(3):265-72. PubMed ID: 10779815
[TBL] [Abstract][Full Text] [Related]
10. Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer.
Risum S; Loft A; Høgdall C; Berthelsen AK; Høgdall E; Lundvall L; Nedergaard L; Engelholm SA
Acta Oncol; 2011 Apr; 50(3):415-9. PubMed ID: 20698810
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery].
Yang ZJ; Wei RJ; Li L
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):898-904. PubMed ID: 23324188
[TBL] [Abstract][Full Text] [Related]
12. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score.
da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G
Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830
[TBL] [Abstract][Full Text] [Related]
13. Radiological assessment of Peritoneal Cancer Index on preoperative CT in ovarian cancer is related to surgical outcome and survival.
Avesani G; Arshad M; Lu H; Fotopoulou C; Cannone F; Melotti R; Aboagye E; Rockall A
Radiol Med; 2020 Aug; 125(8):770-776. PubMed ID: 32239470
[TBL] [Abstract][Full Text] [Related]
14. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
15. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases.
Naik R; Nordin A; Cross PA; Hemming D; de Barros Lopes A; Monaghan JM
Gynecol Oncol; 2000 Aug; 78(2):171-5. PubMed ID: 10926798
[TBL] [Abstract][Full Text] [Related]
16. Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer.
Burger IA; Goldman DA; Vargas HA; Kattan MW; Yu C; Kou L; Andikyan V; Chi DS; Hricak H; Sala E
Gynecol Oncol; 2015 Sep; 138(3):554-9. PubMed ID: 26093061
[TBL] [Abstract][Full Text] [Related]
17. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer.
Aletti GD; Dowdy SC; Gostout BS; Jones MB; Stanhope CR; Wilson TO; Podratz KC; Cliby WA
Obstet Gynecol; 2006 Jan; 107(1):77-85. PubMed ID: 16394043
[TBL] [Abstract][Full Text] [Related]
18. Optimal cytoreduction: is a CT's picture worth a surgeon's word?
Trelis Blanes A; Lago Leal V; Padilla Iserte P; Pérez Martínez R; Belloch Ripollés V; Matute L; Gurrea M; Cardenas Rebollo JM; Domingo Del Pozo S
Surg Oncol; 2023 Aug; 49():101948. PubMed ID: 37210893
[TBL] [Abstract][Full Text] [Related]
19. Poor Prognostic Factors in Patients Undergoing Surgery After Neoadjuvant Chemotherapy for Ovarian, Tubal, or Peritoneal Cancer.
Kaban A; Topuz S; Saip P; Sozen H; Celebi K; Salihoglu Y
J Obstet Gynaecol Can; 2017 Dec; 39(12):1163-1170. PubMed ID: 28784563
[TBL] [Abstract][Full Text] [Related]
20. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
